264 related articles for article (PubMed ID: 29848776)
1. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.
Jarolim P; White WB; Cannon CP; Gao Q; Morrow DA
Diabetes Care; 2018 Jul; 41(7):1510-1515. PubMed ID: 29848776
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
Sharma A; Vaduganathan M; Ferreira JP; Liu Y; Bakris GL; Cannon CP; White WB; Zannad F
J Am Heart Assoc; 2020 Jan; 9(1):e012797. PubMed ID: 31902327
[TBL] [Abstract][Full Text] [Related]
3. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
[TBL] [Abstract][Full Text] [Related]
4. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study.
Ballo P; Betti I; Barchielli A; Balzi D; Castelli G; De Luca L; Gheorghiade M; Zuppiroli A
Clin Res Cardiol; 2016 May; 105(5):421-31. PubMed ID: 26547915
[TBL] [Abstract][Full Text] [Related]
6. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
8. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
9. The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study.
Mishra RK; Judson G; Christenson RH; DeFilippi C; Wu AHB; Whooley MA
Cardiology; 2017; 137(4):201-206. PubMed ID: 28445886
[TBL] [Abstract][Full Text] [Related]
10. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
11. N-terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes.
Hamano K; Nakadaira I; Suzuki J; Gonai M
Vasc Health Risk Manag; 2014; 10():585-9. PubMed ID: 25328404
[TBL] [Abstract][Full Text] [Related]
12. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
Suzuki S; Sugiyama S
Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
Rørth R; Jhund PS; Kristensen SL; Desai AS; Køber L; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur J Heart Fail; 2019 Jan; 21(1):40-49. PubMed ID: 30537261
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT; Morrow DA; Jarolim P; Ren F; Contant CF; Kaur A; Curtis SP; Laine L; Cannon CP; Brune K
J Rheumatol; 2011 Jun; 38(6):1071-8. PubMed ID: 21459935
[TBL] [Abstract][Full Text] [Related]
16. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
17. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
Gaggin HK; Chen-Tournoux AA; Christenson RH; Doros G; Hollander JE; Levy PD; Nagurney JT; Nowak RM; Pang PS; Patel D; Peacock WF; Walters EL; Januzzi JL;
Am Heart J; 2017 Oct; 192():26-37. PubMed ID: 28938961
[TBL] [Abstract][Full Text] [Related]
19. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
[TBL] [Abstract][Full Text] [Related]
20. EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: an observational longitudinal study in patients undergoing coronary artery bypass graft surgery.
Holm J; Vidlund M; Vanky F; Friberg Ö; Håkanson E; Walther S; Svedjeholm R
Br J Anaesth; 2014 Jul; 113(1):75-82. PubMed ID: 24727704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
